In Season 4, Episode 5 of Targeted Talks, Alice P. Cheng, M.D., Ph.D., medical officer for the Targeted Therapeutics 1 Section of the Investigational Drugs Division of the National Cancer Institute’s Cancer Treatment Evaluation Program, explores treatment options. We discuss important studies that are being conducted in the case of alveolar soft part sarcoma (ASPS).
According to Chen, there is only one treatment specifically approved by the FDA to treat ASPS.
“Alveolar soft tissue sarcoma is a very rare tumor. It occurs in less than 1% of all sarcomas, but it is generally not very common to begin with. It’s something,” Chen explains.
Atezolizumab (Tecentriq) approved in December 2022 based on results from an open-label, single-arm study (Study ML39345; NCT03141684) in 49 adult and pediatric patients with unresectable or metastatic ASPS it was done.
Findings showed that at 1200 mg. At doses of 15 mg in adults and 15 mg in children, atezolizumab achieved an objective response rate of 24% (95 CI, 13%–39%), with a duration of response (DOR) of ≥6 months in 67% of patients. Achieved. In addition, his 42% of patients had her DOR ≥12 months. The most common adverse events seen with atezolizumab during trials included musculoskeletal pain (67%), fatigue (55%), rash (47%), cough (45%), nausea, headache, 43%) were included. ).
Atezolizumab is currently being investigated in multiple studies in combination with other therapies. 1 study evaluated Atezolizumab With or Without Bevacizumab (Avastin) in Adult and Pediatric Patients Age 2 years and older to further understand the efficacy, safety and pharmacokinetics of the agent. In another study (Axiom; NCT05333458), atezolizumab was administered to adults over the age of 18 with or without selinexor (Xpovio), explains Chen.
References:
FDA approves atezolizumab for alveolar soft tissue sarcoma. news release. FDA.gov. December 9, 2022. Accessed April 26, 2023. https://bit.ly/3LcwZh6